Early Detection Research Network

Lung

14-3-3 theta, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including 14-3-3 theta.
http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/34/54
Under Review
Three
The findings of this study suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens. Investigation of 14-3-3 theta is ongoing.
a9495de036864d978e1d1db997eaeb6d
no
no
Contents
Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.